


## PHARMACEUTICAL 2020




## MusclePharm Corp Rank 262 of 362





## PHARMACEUTICAL 2020





The relative strengths and weaknesses of MusclePharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MusclePharm Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 827% points. The greatest weakness of MusclePharm Corp is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 932% points.

The company's Economic Capital Ratio, given in the ranking table, is -377%, being 74% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	12,163
Cost of Goods Sold	70,979
Intangible Assets	676
Liabilities, Current	41,541
Liabilities, Non-Current	723
Other Assets	1,485
Other Compr. Net Income	0
Other Expenses	17,698
Other Liabilities	228
Other Net Income	-125
Property and Equipment	216
Research and Development	893
Revenues	79,667
Selling, General and Administrative Expense	8,899

Output Variable	Value in 1000 USD
Assets	14,540
Liabilities	42,492
Expenses	98,469
Stockholders Equity	-27,952
Net Income	-18,927
Comprehensive Net Income	-18,927
Economic Capital Ratio	-377%